ClinicalTrials.gg

Program

HRS-7249

A development code. Also written as “HRS-7249 Injection”, “HRS-7249 injection set” and “HRS-7249 injection”.

In Jiangsu HengRui Medicine's pipeline, ApoC3 siRNA. Its studies are mostly in Hyperlipidemias · Hypertriglyceridemia, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jul 27, 20254 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine43 open or runningphase 2since Jul 27, 2025Jul 16, 2024Jun 2027phase 2 · NCT07308392
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-7249, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2024First study: phase 1 study in HyperlipidemiasFirst studyNCT06541457 · 48 enrolled · China
  2. Jul 27, 2025Phase 2 study in HyperlipidemiasNCT07100418 · 224 enrolled · China
  3. Dec 15, 2025Phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392 · 119 enrolled · China
  4. Aug 21, 2026Phase 2 study in HyperlipidemiasNCT07799688 · 400 planned · China

Ahead

  1. Jun 2027Primary completion: phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392
  2. Oct 15, 2028Primary completion: phase 2 study in HyperlipidemiasNCT07799688

TargetBeta

“ApoC3 siRNA”the company's pipeline, read by Claude · source
“This is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants.”study summary, read by Claude · the study

Other programs on APOC3

ProgramCompanyFurthest phaseStudies
FXR0906Fosun Pharmaphase 22
CS-121rulecorrectsequence-therapeutics-co-ltdearly phase 12

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07799688Hyperlipidemias · China2RecruitingOct 15, 2028400
NCT07308392Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis · China2Active, not recruitingJun 2027119
NCT07100418Hyperlipidemias · China2Active, not recruitingSep 2026224
NCT06541457Hyperlipidemias · China1CompletedJul 30, 202548

How it is read

Names in the registry

  • “HRS-7249 Injection”, 3 entries
  • “HRS-7249 injection set”, 1 entry
  • “HRS-7249 injection”, 1 entry

Codes read as this program: HRS7249.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.